CapsoVision, Inc. (CV)

CapsoVision, Inc. began trading on the Nasdaq Capital Market on July 2, 2025, with an IPO price of $5.00 per share, raising approximately $27.5 million. Following its debut, shares declined by 12% to $4.40. Third-quarter 2025 earnings were reported on November 14, 2025, with both EPS and revenues missing analyst expectations. On November 11, 2025, CapsoVision, Inc. submitted a Breakthrough Device Designation Application to the FDA for a pancreatic cancer screening capsule. David Garcia was appointed as Senior Vice President of Finance and Principal Accounting Officer on November 3, 2025. As of November 21, 2025, the stock closed at $5.23 and has experienced a 52-week range of $3.43 to $5.72.

The provided search results do not contain specific information regarding the demand seasonality for CapsoVision, Inc.'s products and services. The company operates within the healthcare sector's medical devices segment, which generally experiences consistent demand growth due to factors such as an aging population and expanding diagnostic capabilities in healthcare systems. The global gastrointestinal endoscopy market, in which CapsoVision operates, is projected to grow, driven by early cancer screening and an increasing incidence of digestive diseases.

CapsoVision, Inc. is a medical technology company specializing in advanced imaging and AI technologies for capsule endoscopy solutions, focusing on internal GI system imaging for diagnostic and screening purposes. The company's major products include CapsoCam Plus, a capsule endoscopy system for visualizing the small bowel mucosa; CapsoCam Colon, a system for visualizing the colon and detecting and measuring polyps; CapsoColon 3D, an in-development product also aimed at the large intestines (colon); CapsoCloud, a secure, cloud-based software-as-a-service (SaaS) ecosystem; CapsoAccess, a capsule data access system; CapsoView, a data access reading device and software for viewing capsule videos; and CapsoRetrieve, a retrieval kit that uses a magnetic wand to recover the capsule. The company serves gastrointestinal medical practices, clinics, and hospitals, selling its products to distributor customers who then resell them.

CapsoVision, Inc., incorporated in 2005, is headquartered in Saratoga, California, United States. The company serves a broad customer base across the United States and select international markets through a network of direct sales representatives and distribution partners. Its products have obtained regulatory clearances in multiple regions.

The provided search results do not offer specific details about CapsoVision, Inc.'s brand reputation or any events that have explicitly affected it in the past year. The company emphasizes its mission to empower clinicians and patients through innovations in diagnostic imaging, aiming to streamline clinical operations, improve diagnostic outcomes, and enhance patient quality of life. CapsoVision is dedicated to providing medical devices that meet high standards for safety, reliability, and patient care, maintaining compliance with national and international regulatory requirements.

The provided search results do not contain specific details about major institutional and individual owners of CapsoVision, Inc.